Amgen/Apotex Appeals Arguments Aimed At April
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit said it will hear oral arguments on April 4 in Apotex Inc.'s appeal in a lawsuit brought by Amgen Inc., which has been trying to delay the marketing of the biosimilars maker's version of Neulasta (pegfilgrastim) – a product that has yet to receive the FDA's approval.